Janux Therapeutics, Inc. (NASDAQ: JANX), a clinical stage biopharmaceutical company, has been making waves in the biotechnology industry with its innovative immunotherapies. Despite the company's operating loss of $73 million, it has managed to generate an interest income of $12.5 million. The company's shares have seen a 52-week high of $58.69, indicating a strong market presence. However, the stock has also seen a significant short interest, with 2.4 million shares shorted in the prior month, representing a short percent of 0.1303. The company's valuation market value stands at $39.81, while its real value is estimated at $31.71. Despite this discrepancy, analysts remain optimistic about JANX's prospects, with one buy recommendation and five strong buy recommendations. The overall consensus among analysts is a strong buy, with a possible upside price of $70.74, significantly higher than the day's median price of $40.44. However, investors should be aware of the daily balance of power, which currently stands at -0.32, indicating a bearish trend. The market facilitation index is at 2.48, suggesting that the market is facilitating trade. Despite these mixed signals, the accumulation distribution of 0.0595 suggests that the stock is being accumulated rather than distributed, indicating potential future growth. In conclusion, while Janux Therapeutics has some financial challenges, its innovative approach to cancer treatment and strong analyst support suggest that it remains a promising investment opportunity. While some millennials may be indifferent towards the biotechnology sector, it's worthwhile to analyze Janux Therapeutics' current potential. We will discuss why we remain optimistic about a recovery. The returns on investment in Janux Therapeutics over the past few months seem unrelated to market returns. The company's weak fundamental indicators may suggest potential long-term losses for investors. Janux Therapeutics is set to announce its earnings tomorrow, with the next financial report due on May 14, 2024.
Using predictive
technical analysis, we can analyze different prices and returns patterns and
diagnose historical swings to determine the real value of Janux Therapeutics. In general, sophisticated investors focus on analyzing Janux Therapeutics stock price patterns and their correlations with different microeconomic environment and drivers. They apply predictive analytics to build Janux Therapeutics's daily price indicators and compare them against related drivers such as
momentum indicators and various other types of predictive indicators. Using this methodology combined with a more conventional
technical analysis and
fundamental analysis, we attempt to find the most accurate representation of Janux Therapeutics's intrinsic value. In addition to deriving basic predictive indicators for Janux Therapeutics, many experienced traders also check how macroeconomic factors affect Janux Therapeutics price patterns. Please read more on our
technical analysis page or use our predictive modules below to complement your research.
How important is Janux Therapeutics's Liquidity
Janux Therapeutics
financial leverage refers to using borrowed capital as a funding source to finance Janux Therapeutics ongoing operations. It is usually used to expand the firm's asset base and generate returns on borrowed capital. Janux Therapeutics financial leverage is typically calculated by taking the company's all interest-bearing debt and dividing it by total capital. So the higher the debt-to-capital ratio (i.e., financial leverage), the riskier the company. Financial leverage can amplify the potential profits to Janux Therapeutics' owners, but it also increases the potential losses and risk of financial distress, including bankruptcy, if the firm cannot cover its debt costs. The degree of Janux Therapeutics' financial leverage can be measured in several ways, including by ratios such as the debt-to-equity ratio (total debt / total equity), equity multiplier (total assets / total equity), or the debt ratio (total debt / total assets). Please check the
breakdown between Janux Therapeutics's total debt and its cash.
Janux Therapeutics Gross Profit
Janux Therapeutics Gross Profit growth is one of the most critical measures in evaluating the company. The Gross Profit growth rate is calculated simply by comparing Janux Therapeutics previous period's values with its current period's values. Each time period you're measuring should be of equal lengths the increase or decrease, in a company's Gross Profit between two periods. Here we show Janux Therapeutics Gross Profit growth over the last 10 years. Please check Janux Therapeutics'
gross profit and other
fundamental indicators for more details.
Closer look at Janux Therapeutics Mean Deviation
Janux Therapeutics has current Mean Deviation of 8.79. The mean deviation of the equity instrument is the first measure of the distances between each value of security historical prices and the mean. It gives us an idea of how spread out from the center the distribution of returns.
Mean Deviation is the average of the absolute values of the differences between price distribution numbers and their mean. Mean deviation of equity instrument with a lot of historical data is a biased estimator because the time horizon used in calculation will always be much smaller than the entire price history of the equity. The mean deviation is typically used as a measure of dispersion for small investment horizon, otherwise standard deviation is a better measure of dispersion.
Mean Deviation | = | SUM(RET DEV)N |
| = | 8.79 |
| SUM | = | Summation notation |
| RET DEV | = | Sum of return deviations of Janux Therapeutics |
| N | = | Number of calculation points for selected time horizon |
Let's now compare Janux Therapeutics Mean Deviation to its closest peers:
| JANX | 8.787031490358125 |
| MDXG | 1.86 |
| VANI | 9.07 |
| DOMH | 3.01 |
| VCYT | 2.47 |
In the world of investing, it's often said that the trend is your friend.
For Janux Therapeutics (NASDAQ: JANX), the trend has been a bit of a rollercoaster since its IPO in June 2021. Despite a 52-week high of $58.69, the stock's typical price currently sits at $40.23, with Wall Street's target price at $34.25. The company's high beta of 4.3 indicates significant volatility, but with a current ratio of 21.08X and a low debt to equity ratio of 0.07%, the biotech firm demonstrates strong
financial health. However, investors should be cautious as the company reported operating losses of $73M and a probability of bankruptcy at 30.30%. While the company's shares are largely owned by institutions (85.93%), the short percent of 0.1303 suggests some investors are betting against the stock. In conclusion, while Janux Therapeutics presents some promising aspects, its high volatility and operating losses make it a risky investment. .
Our take on Janux Therapeutics small slide
Janux Therapeutics' stock has recently seen a slight decline, with the mean deviation falling to 8.79. This decrease in volatility suggests a more stable trading environment. Despite this, the company's robust pipeline and innovative cancer treatment approach make it an attractive investment. However, investors should monitor the stock closely due to potential rapid market changes. Janux Therapeutics has shown above-average volatility over the chosen time period. Investors should independently assess Janux Therapeutics to ensure their
market timing strategies align with the stock's volatility. Understanding
market volatility trends can help investors time the market effectively. High volatility during bear markets can impact
Janux Therapeutics' stock price and stress investors as they see their shares' value drop, often leading to portfolio rebalancing.
In conclusion, Janux Therapeutics, Inc. is a promising investment opportunity with a strong buy consensus from analysts. The company's innovative approach to cancer treatment, with its lead TRACTr product candidates in preclinical or discovery stage, positions it well for future growth. The highest estimated target price from analysts stands at
$30.25, indicating a potential upside. Furthermore, the possible upside price is a staggering
$70.74, significantly higher than the current market value of $39.81. However, investors should also consider the possible downside price of $11.2. Overall, given the company's strong
fundamentals and positive analyst sentiment, Janux Therapeutics stock is expected to continue its rise in April. .
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectEditorial Staff
Gabriel Shpitalnik is a Member of Macroaxis Editorial Board. Gabriel is a young entrepreneur and writes predominantly on the business, technology, and finance sector. He likes to analyze different equity instruments across a wide range of industries focusing primarily on consumer products and evolving technologies.
View Profile This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Gabriel Shpitalnik do not own shares of Janux Therapeutics. Please refer to our
Terms of Use for any information regarding our disclosure principles.
Would you like to provide feedback on the content of this article?
You can get in touch with us directly or send us a quick note via email to
[email protected]